Le Lézard
Classified in: Health, Science and technology
Subject: MRR

Glycated Albumin Assay Market Projected to Reach $360.92 million by 2030 - Exclusive Report by 360iResearch


PUNE, India, April 23, 2024 /PRNewswire/ -- The report titled "Glycated Albumin Assay Market by Product (Animal Glycated Albumin Assay, Human Glycated Albumin Assay), Application (Prediabetes, Type 1 Diabetes, Type 2 Diabetes), End User - Global Forecast 2024-2030" is now available on 360iResearch.com's offering, presents an analysis indicating that the market projected to grow from a size of $217.29 million in 2023 to reach $360.92 million by 2030, at a CAGR of 7.51% over the forecast period.

360 iResearch Logo

"The Global Rise of Glycated Albumin Assays"

The glycated albumin assay, an innovative diagnostic tool, is gaining importance worldwide for its ability to accurately measure glycated albumin levels in the blood, providing an essential alternative for diabetes management, especially for individuals facing inaccuracies with traditional HbA1c tests due to conditions such as hemoglobinopathies, recent blood transfusions, or chronic kidney or liver diseases. This test is essential in modifying diabetes treatment plans swiftly, aiming for improved short-term blood glucose regulation. With diabetes prevalence on the rise and a growing emphasis on vigilant monitoring and control of blood glucose levels, the need for precise and dependable testing methods such as the glycated albumin assay is more urgent than ever. Challenges include variations in reimbursement policies and regulatory landscapes across different countries and the expanding healthcare infrastructure in emerging markets. Ongoing research into new glucose regulation biomarkers is set to propel the growth of the glycated albumin assay market. In the Americas, the demand is driven by a high prevalence of diabetes and well-established healthcare systems. In Europe, the approach is focused on early disease detection among its aging population, and the Asia-Pacific market is expanding rapidly owing to increasing diabetes awareness and technological advancements; the adoption of glycated albumin assays is becoming more widespread. Furthermore, the rise in lifestyle-related diseases has spurred initiatives to adopt such state-of-the-art diagnostic techniques in the Middle East and Africa, underscoring a global movement toward better diabetes management and control.

Download Sample Report @ https://www.360iresearch.com/library/intelligence/glycated-albumin-assay

"Global Initiatives Enhance Early Diabetes Detection through Advanced Screening Programs"

Governments around the world are implementing efforts to combat the rising tide of diabetes by launching comprehensive screening initiatives aimed at early detection, which is essential in management of the disease and prevention of severe complications. In the United States, the National Diabetes Prevention Program, supported by the Centers for Disease Control and Prevention (CDC), is at the forefront, promoting regular screenings for prediabetes and Type 2 diabetes, essential steps in curbing the disease's progression. Across the Atlantic, the UK's EarLy Surveillance for Autoimmune Diabetes (ELSA) project is pioneering early detection and management of type 1 diabetes among children. Central to these efforts is the inclusion of the glycated albumin assay, a key diagnostic tool recommended by health authorities in Europe and Asia for those at risk or already diagnosed with diabetes. These governmental health initiatives underscore a global commitment to integrating cutting-edge technologies, like the glycated albumin assay, in the fight against diabetes, emphasizing the importance of early detection in safeguarding public health.

"Glycated Albumin Assay Is A Key to Early Diabetes Management and Insightful Lifestyle Adjustments"

In diabetes management and prevention, the glycated albumin assay emerges as a pivotal tool, especially for those at the precipice of diabetes, known as prediabetics. Prediabetes, a condition marked by slightly elevated blood glucose levels, however not high enough to diagnose diabetes, can often be a wake-up call. The glycated albumin assay is valuable, offering short-term fluctuations in blood glucose that could guide timely interventions to prevent the development of Type 2 diabetes. This assay is essential for prediabetics, allowing them to witness the immediate effects of lifestyle adjustments, such as exercise and diet modifications, on their blood sugar levels. Moreover, for individuals battling Type 1 diabetes, where the immune system attacks cells producing insulin, glycated albumin assays serve as a crucial adjunct to the long-standing Hemoglobin A1c test, offering faster, more current insights into glucose levels and thereby aiding in fine-tuning treatment plans. Its application in managing Type 2 diabetes is exceptional. Providing an average of blood glucose over a shorter span of about two to four weeks than traditional markers empowers individuals with Type 2 diabetes to swiftly gauge the impact of changes in their lifestyle or medication, ensuring more effective management of the condition.

Request Analyst Support @ https://www.360iresearch.com/library/intelligence/glycated-albumin-assay

"Asahi Kasei Corporation at the Forefront of Glycated Albumin Assay Market with a Strong 22.09% Market Share"

The key players in the Glycated Albumin Assay Market include Laboratory Corporation of America Holdings, EKF Diagnostics Holdings by IBL PLC, Asahi Kasei Corporation, Thermo Fisher Scientific Inc., Cardinal Health, Inc., and others. These prominent players focus on strategies such as expansions, acquisitions, joint ventures, and developing new products to strengthen their market positions.

"Introducing ThinkMi: Revolutionizing Market Intelligence with AI-Powered Insights for the Glycated Albumin Assay Market"

We proudly unveil ThinkMi, a cutting-edge AI product designed to transform how businesses interact with the Glycated Albumin Assay Market. ThinkMi stands out as your premier market intelligence partner, delivering unparalleled insights with the power of artificial intelligence. Whether deciphering market trends or offering actionable intelligence, ThinkMi is engineered to provide precise, relevant answers to your most critical business questions. This revolutionary tool is more than just an information source; it's a strategic asset that empowers your decision-making with up-to-the-minute data, ensuring you stay ahead in the fiercely competitive Glycated Albumin Assay Market. Embrace the future of market analysis with ThinkMi, where informed decisions lead to remarkable growth.

Ask Question to ThinkMi @ https://app.360iresearch.com/library/intelligence/glycated-albumin-assay

"Dive into the Glycated Albumin Assay Market Landscape: Explore 184 Pages of Insights, 284 Tables, and 22 Figures"

  1. Preface
  2. Research Methodology
  3. Executive Summary
  4. Market Overview
  5. Market Insights
  6. Glycated Albumin Assay Market, by Product
  7. Glycated Albumin Assay Market, by Application
  8. Glycated Albumin Assay Market, by End User
  9. Americas Glycated Albumin Assay Market
  10. Asia-Pacific Glycated Albumin Assay Market
  11. Europe, Middle East & Africa Glycated Albumin Assay Market
  12. Competitive Landscape
  13. Competitive Portfolio

Inquire Before Buying @ https://www.360iresearch.com/library/intelligence/glycated-albumin-assay

Related Reports:

  1. Type 2 Diabetes Drugs Market - Global Forecast 2024-2030
  2. Diabetes Diagnostics Market - Global Forecast 2024-2030
  3. Diabetes Drugs Market - Global Forecast 2024-2030

About 360iResearch

Founded in 2017, 360iResearch is a market research and business consulting company headquartered in India, with clients and focus markets spanning the globe.

We are a dynamic, nimble company that believes in carving ambitious, purposeful goals and achieving them with the backing of our greatest asset ? our people.

Quick on our feet, we have our ear to the ground when it comes to market intelligence and volatility. Our market intelligence is diligent, real-time and tailored to your needs, and arms you with all the insight that empowers strategic decision-making.

Our clientele encompasses about 80% of the Fortune Global 500, and leading consulting and research companies and academic institutions that rely on our expertise in compiling data in niche markets. Our meta-insights are intelligent, impactful and infinite, and translate into actionable data that support your quest for enhanced profitability, tapping into niche markets, and exploring new revenue opportunities.

Contact 360iResearch
Mr. Ketan Rohom
360iResearch Private Limited,
Office No. 519, Nyati Empress,
Opposite Phoenix Market City,
Vimannagar, Pune, Maharashtra,
India - 411014.
Email: [email protected]
USA: +1-530-264-8485
India: +91-922-607-7550

To learn more, visit 360iresearch.com or follow us on LinkedIn, Twitter, and Facebook.

Logo: https://mma.prnewswire.com/media/2359256/360iResearch_Logo.jpg

 


These press releases may also interest you

at 19:13
The BC Association of Clinical Counsellors (BCACC) is pleased that the legislative regulation of Psychotherapy under the Health Professions Act and eventually under the new Health Professions & Occupations Act is moving forward, as indicated in the...

at 18:50
The Rotary Club of Southern Frederick County spent a rewarding morning with Sleep in Heavenly Peace (SHP) on May 18, 2024, donating both their time and a check for $2,500 to support the building of beds for children in need. The club members came...

at 18:30
Legislation holding oil drillers liable for health harms caused by their wells within a half mile of a community failed to come up for a vote on the Assembly floor by the deadline for bills to move to the Senate....

at 17:21
On Tuesday, May 28, the Second Gentleman will deliver remarks at an event to raise awareness about the physical and mental health challenges affecting young people. The Second Gentleman will uplift the Biden-Harris Administration's actions to tackle...

at 17:05
Agenus Inc. ("Agenus") , a leader in discovering and developing novel immunological agents to treat various cancers, today announced that the Compensation Committee of Agenus' Board of Directors granted inducement awards to Eric Olson, in connection...

at 16:46
Vanda Pharmaceuticals Inc. (Vanda) today announced that the Company's Board of Directors (the "Board") carefully reviewed the revised unsolicited proposal from Future Pak, LLC ("FP") to acquire the Company for $7.25 to $7.75 per share in cash plus...



News published on and distributed by: